Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review. [PDF]
Ekedahl H +5 more
europepmc +1 more source
A proposed mechanistic framework of systemic lupus erythematosus (SLE) and autoimmune thyroid disease (AITD) pathogenesis. In Stage 1, genetically susceptible individuals harbor risk variants within major histocompatibility complex (HLA) and non‐HLA loci that impair central and peripheral immune tolerance mechanisms within the thymic and peripheral ...
Elisa Elisa +3 more
wiley +1 more source
Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley +1 more source
Cardiomyocyte Janus kinase 1 (JAK1) signaling is required for cardiac homeostasis and cytokine-dependent activation of STAT3. [PDF]
Subramani A +6 more
europepmc +1 more source
Circular RNA PIP5K1A act as microRNA-552-3p sponge to regulates inflammation, oxidative damage in glucolipotoxicity-induced pancreatic INS-1 β-cells via Janus kinase 1. [PDF]
Ren L.
europepmc +1 more source
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud +14 more
wiley +1 more source
ARTEMISIA: a mechanistic study of a novel Janus kinase 1 inhibitor to advance molecular understanding and precision medicine in asthma. [PDF]
Dosanjh DPS +9 more
europepmc +1 more source
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. [PDF]
Zhao Y +13 more
europepmc +1 more source
Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial. [PDF]
Cheng Y +31 more
europepmc +1 more source
The Impact of Common Medications on Male Fertility: An Updated Systematic Review
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli +7 more
wiley +1 more source

